John L. Berk, MD

Associate Professor, Medicine

John Berk
617.358.4774
72 E. Concord St Housman (R)

Biography

Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.

Education

  • Case Western Reserve University, MD
  • Wesleyan University, BA

Publications

  • Published on 8/31/2018

    Waddington-Cruz M, Ackermann EJ, Polydefkis M, Heitner SB, Dyck PJ, Barroso FA, Wang AK, Berk JL, Dyck PJB, Monia BP, Hughes SG, Tai L, Jesse Kwoh T, Jung SW, Coelho T, Benson MD, Gertz MA. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 2018 Aug 31; 1-9. PMID: 30169969.

    Read at: PubMed
  • Published on 7/21/2018

    Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Jul 21; 1-8. PMID: 30032658.

    Read at: PubMed
  • Published on 7/5/2018

    Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 07 05; 379(1):11-21. PMID: 29972753.

    Read at: PubMed
  • Published on 7/5/2018

    Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 07 05; 379(1):22-31. PMID: 29972757.

    Read at: PubMed
  • Published on 6/25/2018

    Klimtchuk ES, Prokaeva T, Frame NM, Abdullahi HA, Spencer B, Dasari S, Cui H, Berk JL, Kurtin PJ, Connors LH, Gursky O. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proc Natl Acad Sci U S A. 2018 07 10; 115(28):E6428-E6436. PMID: 29941560.

    Read at: PubMed
  • Published on 6/19/2018

    Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018 Oct; 5(5):772-779. PMID: 29916559.

    Read at: PubMed
  • Published on 6/11/2018

    Copperman TS, Truong MT, Berk JL, Sobel RK. External beam radiation for localized periocular amyloidosis: a case series. Orbit. 2018 Jun 11; 1-7. PMID: 29889595.

    Read at: PubMed
  • Published on 3/8/2018

    Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid. 2018 Jun; 25(2):139-140. PMID: 29516761.

    Read at: PubMed
  • Published on 2/9/2018

    Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar; 25(1):62-67. PMID: 29424556.

    Read at: PubMed
  • Published on 2/1/2018

    Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail. 2018 Feb; 11(2):e004000. PMID: 29449366.

    Read at: PubMed

View 73 more publications: View full profile at BUMC

View all profiles